Fuller & Thaler Asset Management
AMRI

Fuller & Thaler Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

Fuller & Thaler Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-354,350
Closed -$4.57M – 650
2013
Q3 		$4.57M Sell
354,350
-5,400
-2% -$66.4K 0.27% 145
2013
Q2 		$4.27M Buy
+359,750
New +$3.9M 0.3% 135

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Fuller & Thaler Asset Management's AMRI Position: Q4 2013 in Review

Fuller & Thaler Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q4 2013, closing a stake of 354,350 shares — an estimated $4.57M sold.

Fuller & Thaler Asset Management first reported a position in AMRI in Q2 2013 and held it in 2 quarters. The position peaked at $4.57M in Q3 2013. 118 funds tracked by Wall St. Rank hold AMRI as of Q4 2013.

  • Fuller & Thaler Asset Management reported no remaining Albany Molecular Research Inc position as of Q4 2013 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 354,350 Albany Molecular Research Inc shares in Q4 2013, an estimated $4.57M.
  • Fuller & Thaler Asset Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 2 quarters.
  • Fuller & Thaler Asset Management's Albany Molecular Research Inc position peaked at $4.57M in Q3 2013.
  • 118 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2013.

Based on Fuller & Thaler Asset Management's 13F filing for Q4 2013, filed 13 Feb 2014.